MOCS2 and small cell lung carcinoma: Future research directions should include in vitro and in vivo studies to verify the mechanistic contributions of MOCS2, USP39, SMYD2, GFPT1, and PRKRIR to metabolic reprogramming and immune modulation in SCLC.